5-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)-3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridine | 1351476-74-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 5-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)-3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridine
• 英文别名: US10485800, Example 185；5-[4-[(4,4-difluoropiperidin-1-yl)methyl]phenyl]-3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridine
• CAS: 1351476-74-8
• 化学式: C₂₇H₂₄F₂N₄
• 分子量: 442.511
• InChiKey: CYTMYPAQFJPTPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  47.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-溴-3-碘-7-氮杂吲哚 在 bis-triphenylphosphine-palladium(II) chloride sodium hydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 、 mineral oil 为溶剂， 反应 3.5h， 生成 5-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)-3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  [EN] BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE
  [FR] HÉTÉROARYLES BICYCLIQUES FORMANT INHIBITEURS DE LA KINASE ET PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2011149950A3

文献信息

• [EN] MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES<br/>[FR] INHIBITEURS DE KINASE DE LIGNAGE MIXTE POUR DES THÉRAPIES POUR LE VIH/SIDA
  申请人：UNIV ROCHESTER

  公开号：WO2014085795A1

  公开（公告）日：2014-06-05

  Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

  揭示了治疗感染逆转录病毒的个体的方法，包括向个体施用有效量的混合谱系激酶抑制剂和抗逆转录病毒药物。此外，还揭示了治疗感染逆转录病毒的个体的方法，包括向个体施用配制成含有表面活性剂的结晶纳米粒子的抗逆转录病毒药物，以及MLK抑制剂。进一步揭示了治疗感染逆转录病毒的个体的方法，包括向个体施用包含抗逆转录病毒和MLK抑制剂的组合物，该组合物配制成含有表面活性剂的结晶纳米粒子。还揭示了包含抗逆转录病毒药物、MLK抑制剂和表面活性剂的组合物，其中该组合物是结晶纳米粒子。还揭示了包含MLK抑制剂与其他药物在纳米粒形式中的组合物，以及其使用方法。
• BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE
  申请人：Gelbard Harris A.

  公开号：US20130203755A1

  公开（公告）日：2013-08-08

  Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

  提供了一些具有抑制激酶活性的化合物，包括混合谱系激酶。还提供了制药组合物、制备这些化合物的方法、合成中间体以及使用这些化合物的方法，可单独使用或与其他治疗药物结合，用于治疗受混合谱系激酶抑制影响的疾病和病况。还提供了抑制混合谱系激酶的方法，用于治疗神经精神障碍。
• MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150297587A1

  公开（公告）日：2015-10-22

  Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

  本发明涉及治疗感染逆转录病毒的个体的方法，包括向个体施用混合谱系激酶抑制剂和抗逆转录病毒药物的有效剂量。在进一步的方面，本发明涉及治疗感染逆转录病毒的个体的方法，包括向个体施用配制成晶体纳米粒子的抗逆转录病毒药物，该纳米粒子包括表面活性剂和MLK抑制剂。还公开了治疗感染逆转录病毒的个体的方法，包括向个体施用包含抗逆转录病毒和MLK抑制剂的组合物，该组合物配制成晶体纳米粒子，其中包含表面活性剂。此外，还公开了包含抗逆转录病毒药物、MLK抑制剂和表面活性剂的组合物，其中该组合物是晶体纳米粒子。还公开了将MLK抑制剂与其他药物配制成纳米粒子形式的组合物及其使用方法。
• US8846909B2
  申请人：——

  公开号：US8846909B2

  公开（公告）日：2014-09-30